BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
BioAge Labs (NASDAQ:BIOA), a clinical-stage biotechnology company focused on innovative treatments for metabolic diseases such as obesity, announced its second quarter 2025 earnings on August 6, 2025. The most significant news from the release was the introduction of $2.41 million in collaboration revenue (GAAP) for Q2 2025, an increase from zero in the prior year and ahead of consensus expectations. While the company posted a net loss per share of $(0.60) (GAAP) for Q2 2025, the quarter saw expenses and net loss (GAAP) rise as clinical investment accelerated. The results highlight both operational progress—fuelled by drug pipeline advancements and new partnerships—and the inherently high costs of early-stage drug development, visible in expanding research and administrative expenses.
Source: Analyst estimates for the quarter provided by FactSet.
BioAge Labs is a biotechnology company developing therapies for age-related diseases, focusing especially on metabolic disorders like obesity. It aims to harness its proprietary discovery platform to discover novel drug targets, then move those candidates into clinical development either independently or in partnership with major pharmaceutical firms.
Source Fool.com
